Eylea®
Aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor for VEGF-A, VEGF-B, and PlGF. It is the most widely used intravitreal anti-VEGF agent.
| Dosage Form | Intravitreal Injection (Solution) |
| Strength | 2 mg/0.05mL; 8 mg/0.07mL (Eylea HD) |
| Storage | Store at 2–8°C. Protect from light. Do not freeze. |
| Category | Ophthalmics |
| Availability | Available for Transfer |
Wet age-related macular degeneration (AMD); diabetic macular edema (DME); macular edema following retinal vein occlusion (RVO); diabetic retinopathy; retinopathy of prematurity.
Fusion protein combining VEGF receptor 1 and 2 extracellular domains with human IgG1 Fc. Binds VEGF-A, VEGF-B, and PlGF with higher affinity than native receptors, preventing neovascularization and vascular permeability.
Each Burrard Pharmaceuticals technology transfer package for Aflibercept includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier templates — available through Burrard Intelligence subscription.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Our team can deliver the complete know-how package within 2–21 business days. Book a consultation to discuss your specific requirements.